Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers

Publication date: Available online 18 May 2018
Source:Critical Reviews in Oncology/Hematology
Author(s): Chiara Di Tucci, Michele Carlo Schiavi, Pierangelo Faiano, Ottavia D'Oria, Giovanni Prata, Valentina Sciuga, Andrea Giannini, Innocenza Palaia, Ludovico Muzii, Pierluigi Benedetti Panici
Treatments for gynecological cancer include surgery, chemotherapy, and radiation. However, overall survival is not improved, and novel approaches are needed. Immunotherapy has been proven efficacious in various types of cancers and multiple approaches have been recently developed. Since numerous gynecological cancers are associated to human papilloma virus (HPV) infections, therapeutic vaccines, targeting HPV epitopes, have been developed. The advancing understanding of the immune system, regulatory pathways and tumor microenvironment have produced a major interest in immune checkpoint blockade, Indeed, immune checkpoint molecules are important clinical targets in a wide variety of tumors, including gynecological.In this review, we will describe the immunotherapeutic targets and modalities available and review the most recent immunotherapeutic clinical trials in the context of gynecological cancers. The synergic results obtained from the combination of HPV therapeutic vaccines with radiotherapy, chemotherapy, or immune checkpoint inhibitors, may underlie the potential for a novel therapeutic scenario for these tumors.



https://ift.tt/2x3lS7F